Dr. Michaela Dinan is an Associate Professor of Epidemiology in the Yale School of Public Health, and Co-Leader of the Cancer Prevention and Control Research Program at the Yale Comprehensive Cancer Center, Yale School of Medicine. She is also a member of the Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center. Dr. Dinan has extensive research expertise in leveraging existing real-world data sources as well as novel data linkages to examine oncology outcomes.
Dr. Dinan is a health services researcher by training and she specializes in using econometric and epidemiologic methodologies to analyze complex datasets. Specifically, Dr. Dinan's research involves issues related to advances in cancer care technologies, such as emerging treatments and diagnostics, and how these advances in technologies impact different cancer outcomes and experiences such as access, quality of care, cost of care, and health disparities.
Dr. Dinan has led studies funded by the National Institutes of Health, the American Cancer Society, and the Agency for Healthcare Research and Quality. She is currently leading an NCI-funded R01 study examining multi-level factors that contribute to disparities in access and adherence to oral anticancer agents for patients with kidney cancer. Dr. Dinan is also leading a study funded by the ACS to develop and validate risk prediction algorithms to inform efficient and high-quality care for long-term cancer survivors.